Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 10, 2017 - Issue 7
Submit an article Journal homepage
3,443
Views
12
CrossRef citations to date
0
Altmetric
Review

A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus

A. AvogaroDepartment of Internal Medicine, University of Padova, Padova, ItalyCorrespondence[email protected]
View further author information
,
A. GiaccariUniversità Cattolica del Sacro Cuore, Section of Endocrinology and Metabolic Diseases, Policlinico Gemelli, Rome, ItalyView further author information
,
P. FiorettoDepartment of Internal Medicine, University of Padova, Padova, ItalyView further author information
,
S. GenoveseDepartment of Cardiovascular and Metabolic Diseases, IRCCS Multimedica, Sesto San Giovanni, Milan, ItalyView further author information
,
F. PurrelloDepartment of Biomedical Sciences and Biotechnology, Section of Biology and Genetics Giovanni Sichel, Unit of Biomolecular, Genome and Complex Systems Biomedicine, Catania, ItalyView further author information
,
F. GiorginoSection of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, ItalyView further author information
&
S. Del PratoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, ItalyView further author information
 show all
Pages 763-772 | Received 12 Jan 2017, Accepted 20 Apr 2017, Published online: 02 May 2017

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mattia Galli, Domenico D’Amario, Carmelo Sofia, Marcello Vaccarella, Filippo Crea & Nadia Aspromonte. (2018) Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Expert Opinion on Drug Metabolism & Toxicology 14:12, pages 1273-1285.
Read now
André J. Scheen. (2017) Pharmacological management of type 2 diabetes: what’s new in 2017?. Expert Review of Clinical Pharmacology 10:12, pages 1383-1394.
Read now

Articles from other publishers (10)

V. Pallarés, C. Escobar, I. Egocheaga & J.C. Obaya. (2021) Impacto de dapagliflozina en los factores de riesgo cardiovascular. Más allá del control de la glucemia. Medicina de Familia. SEMERGEN.
Crossref
Bergur V. Stefánsson, Hiddo J.L. Heerspink, David C. Wheeler, C. David Sjöström, Peter J. Greasley, Peter Sartipy, Valerie Cain & Ricardo Correa-Rotter. (2021) Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline. Data in Brief 37, pages 107237.
Crossref
Kiran Shabir, James E. Brown, Islam Afzal, Seley Gharanei, Martin O. Weickert, Thomas M. Barber, Ioannis Kyrou & Harpal S. Randeva. (2021) Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence. Cytokine & Growth Factor Reviews 60, pages 120-132.
Crossref
Bergur V. Stefánsson, Hiddo J.L. Heerspink, David C. Wheeler, C. David Sjöström, Peter J. Greasley, Peter Sartipy, Valerie Cain & Ricardo Correa-Rotter. (2020) Correction of anemia by dapagliflozin in patients with type 2 diabetes. Journal of Diabetes and its Complications 34:12, pages 107729.
Crossref
Lynn M. NeilsonElizabeth C.S. SwartChester B. GoodWilliam H. ShrankRochelle Henderson, Chronis ManolisNatasha Parekh. (2019) Identifying Outcome Measures for Type 2 Diabetes Value-Based Contracting Using the Delphi Method. Journal of Managed Care & Specialty Pharmacy 25:3, pages 324-331.
Crossref
Kyu Hang LeeSang Don LeeNamdu KimKwee Hyun SuhYoung Hoon KimSang Soo Sim. (2019) Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo . The Korean Journal of Physiology & Pharmacology 23:1, pages 55.
Crossref
Rinkoo Dalan. (2018) Sodium–Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus. Cardiology in Review 26:6, pages 312-320.
Crossref
André J. Scheen. (2018) Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circulation Research 122:10, pages 1439-1459.
Crossref
O V Marukhina, O G Berestneva, Yu A Emelyanova, S V Romanchukov, L Petrova, C Lombardo & N V Kozlova. (2018) Basic physiological systems indicator's informative assessment for children and adolescents obesity diagnosis tasks. Journal of Physics: Conference Series 1015, pages 032091.
Crossref
Roberta Malaguarnera, Veronica Vella, Maria Luisa Nicolosi & Antonino Belfiore. (2017) Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?. Frontiers in Endocrinology 8.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.